Monday, 27 July 2015

In vitro evaluation of the antiviral properties of Shilajit and investigation of its mechanisms of action

Volume 166, 26 May 2015, Pages 129–134


Ethnopharmacological relevance

Shilajit, a herbomineral substance exuded from rocks in steep mountainous regions, has been used for thousands of years by the Indian Ayurvedic and Siddha systems of traditional medicine to relieve ailments and enhance quality of life. Although a large number of therapeutic properties have been ascribed to Shilajit, its therapeutic potential is still largely unexplored by modern research and many of its claimed bioactivities lack scientific validation. The present study was undertaken to investigate the antiviral activity of Shilajit against a panel of viruses including herpes simplex type 1 and 2 (HSV-1, HSV-2), human cytomegalovirus (HCMV), human respiratory syncytial virus (RSV), human rotavirus (HRV), and vesicular stomatitis virus (VSV).

Materials and methods

The antiviral activity of Shilajit was assayed in vitro by plaque reduction and virus yield assays and the major mechanism of action was investigated by virucidal and time-of-addition assays.


Shilajit exhibited a dose-dependent inhibitory activity against HSV1, HSV2, HCMV, and RSV infectivity in vitro (EC50 values: 31.08 μg/ml, 12.85 μg/ml, 34.54 μg/ml, and 30.35 μg/ml, respectively), but was inactive against HRV and VSV. Humic acid, a constituent of Shilajit, displayed the same spectrum of activity. Partial virus inactivation and interference with virus attachment were both found to contribute to the antiviral activity of Shilajit.


The results of the present study demonstrate that Shilajit is endowed with broad, yet specific, antiviral activity in vitro and constitutes a natural source of antiviral substances. Further work remains to be done to assess its efficacy in vivo.

Graphical abstract

Image for unlabelled figure


  • Shilajit;
  • Ayurvedic medicine;
  • Humic acid;
  • Antiviral;
  • Mechanism of action;
  • Virus

Corresponding author. Tel.: +39 011 6705484; fax: +39 011 2365484.
VC and MD contributed equally to this work.